Outcomes of Intradetrusor Onabotulinum Toxin A Therapy in Overactive Bladder Refractory to Sacral Neuromodulation
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: Intradetrusor onabotulinum toxin A (BTXA) and sacral neuromodulation (SNM) are effective third-line therapies for overactive bladder (OAB). We aimed to measure the outcomes of BTXA for treatment of OAB refractory to initial SNM and identify patient characteristics associated with these outcomes. Methods: This retrospective cohort study included patients who failed to respond to initial SNM treatment for OAB and subsequently received BTXA at a single provider’s clinic between January 2013 and December 2016. Treatment successes were defined as patients willing to continue BTXA or who found symptom relief whereas treatment failures discontinued BTXA due to adverse effects or lack of symptom relief. Symptoms and patient-reported outcomes on validated questionnaires were compared before the initial BTXA trial to 2 months after the last BTXA treatment. The SNM failure BTXA groups were also compared to BTXA SNM naïve groups. Results: Of 18 patients who received BTXA after failed SNM treatment, 7 (39%) achieved treatment success. Successfully treated patients demonstrated decreased urinary frequency from a median 11 voids/day pre-BTXA to 8 voids/day with BTXA (P=0.042). Patients whose treatment failed reported increased complaints of a weak urinary stream (P=0.03) and higher frequency of straining to urinate (P=0.016) than the successful treatment group pre-BTXA. Compared to BTXA patients without prior SNM, the odds of failing BTXA after initial SNM were 3.6 times higher (P=0.016). Conclusions: BTXA appears effective for OAB refractory to SNM, although the success rate is lower compared to BTXA patients without SNM exposure.
Abstract
Purpose: Intradetrusor onabotulinum toxin A (BTXA) and sacral neuromodulation (SNM) are effective third-line therapies for overactive bladder (OAB). We aimed to measure the outcomes of BTXA for treatment of OAB refractory to initial SNM and identify patient characteristics associated with these outcomes. Methods: This retrospective cohort study included patients who failed to respond to initial SNM treatment for OAB and subsequently received BTXA at a single provider’s clinic between January 2013 and December 2016. Treatment successes were defined as patients willing to continue BTXA or who found symptom relief whereas treatment failures discontinued BTXA due to adverse effects or lack of symptom relief. Symptoms and patient-reported outcomes on validated questionnaires were compared before the initial BTXA trial to 2 months after the last BTXA treatment. The SNM failure BTXA groups were also compared to BTXA SNM naïve groups. Results: Of 18 patients who received BTXA after failed SNM treatment, 7 (39%) achieved treatment success. Successfully treated patients demonstrated decreased urinary frequency from a median 11 voids/day pre-BTXA to 8 voids/day with BTXA (P=0.042). Patients whose treatment failed reported increased complaints of a weak urinary stream (P=0.03) and higher frequency of straining to urinate (P=0.016) than the successful treatment group pre-BTXA. Compared to BTXA patients without prior SNM, the odds of failing BTXA after initial SNM were 3.6 times higher (P=0.016). Conclusions: BTXA appears effective for OAB refractory to SNM, although the success rate is lower compared to BTXA patients without SNM exposure.
참고문헌 (29)
- South M, "Urogynecology and reconstructive pelvic surgery", pp.513~541 (2015), Saunders
- Coyne KS, "The prevalence of lower urinary tract symptoms(LUTS)and overactive bladder(OAB)by racial", ethnic group and age : results from OAB-POLL, 2013, pp.32, 230~237
- Ju R, "Anticholinergic medication use for female overactive bladder in the ambulatory setting in the United States", Int Urogynecol J, 25, pp.479~484 (2014)
- Milsom I, "Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States : results from EpiLUTS", Urology, 80, pp.90~96 (2012)
- Chu CM, "Procedure-based management of urgency urinary incontinence in the older woman", Curr Geriatr Rep, 6, pp.98~113 (2017)
- Jayadevappa R, "Association between overactive bladder treatment and falls among older adults", Neurourol Urodyn, 37, pp.2688~2694 (2018)
- Gormley EA, "Diagnosis and treatment of overactive bladder(nonneurogenic)in adults : AUA", SUFU guideline amendment, 2015, pp.193, 1572~1580
- Zahner PM, "What is the role of additional pharmacotherapy and neuromodulation in patients with marginal benefit from botulinum toxin injection?", Curr Urol Rep, 19, pp.91~ (2018)
- Glinski RW, "Refractory overactive bladder : beyond oral anticholinergic therapy", Indian J Urol, 23, pp.166~173 (2007)
- Al-zahrani AA, "Long-term outcome and surgical interventions after sacral neuromodulation implant for lower urinary tract symptoms : 14-year experience at 1 center", J Urol, 185, pp.981~986 (2011)
- Denys P, "Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder : a multicentre, double-blind, randomised, placebo-controlled doseranging study", Eur Urol, 61, pp.520~529 (2012)
- Smits MA, "Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy", J Urol, 190, pp.2148~2152 (2013)
- Hoag N, "Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment", Neurourol Urodyn, 36, pp.1377~1381 (2017)
- Siegel S, "Three-year follow-up results of a prospective, multicenter study in overactive bladder subjects treated with sacral neuromodulation", Urology, 94, pp.57~63 (2016)
- Barry MJ, "The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association", J Urol, 148, pp.1549~1557 (1992)
- Suskind AM, "The Michigan Incontinence Symptom Index(M-ISI) : a clinical measure for type, severity, and bother related to urinary incontinence", Neurourol Urodyn, 33, pp.1128~1134 (2014)
- Rivas DA, "Utility of the American Urological Association symptom index in the diagnosis of women with voiding dysfunction", Int Urogynecol J, 5, pp.202~207 (1994)
- Lawrence GW, "Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of transmitters from efferent fibers", J Pharmacol Exp Ther, 334, pp.1080~1086 (2010)
- Malde S, "What is the exact working mechanism of botulinum toxin A and sacral nerve stimulation in the treatment of overactive bladder", detrusor overactivity? ICI-RS 2017, 2018, pp.37(S4), S108~116
- Leng WW, "How sacral nerve stimulation neuromodulation works", Urol Clin North Am, 32, pp.11~18 (2005)
- Abello A, "Electrical neuromodulation in the management of lower urinary tract dysfunction : evidence, experience and future prospects", Ther Adv Urol, 10, pp.165~173 (2018)
- Amend B, "How does neuromodulation work", Neurourol Urodyn, 30, pp.762~765 (2011)
- Aponte MM, "Urogynecology and reconstructive pelvic surgery", pp.566~580 (2015), Saunders
- Schmid DM, "Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics", J Urol, 17, pp.177~185 (2006)
- Goldman HB, "Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder(OAB)", BJU Int, 111, pp.8~ (2013)
- Veeratterapillay R, "Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type? A injections for detrusor overactivity", Int J Urol, 21, pp.175~178 (2014)
- Leitner L, "More than 15 years of experience with intradetrusor onabotulinumtoxina injections for treating refractory neurogenic detrusor overactivity : lessons to be learned", Eur Urol, 70, pp.522~528 (2016)
- Laviana A, "Sacral neuromodulation for refractory overactive bladder, interstitial cystitis, and painful bladder syndrome", Neurosurg Clin N Am, 25, pp.33~46 (2014)
- Amundsen CL, "OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women : a randomized clinical trial", JAMA, 316, pp.1366~1374 (2016)